Oncolytic herpes viruses, chemotherapeutics, and other cancer drugs by Braidwood, L. et al.
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 
 
 
 
 
 
 
Braidwood, L., Graham, S.V., Graham, A., and Conner, 
J. (2013) Oncolytic herpes viruses, chemotherapeutics, and other cancer 
drugs. Oncolytic Virotherapy, 2 . pp. 57-74. ISSN 2253-1572 
 
Copyright © 2013 Braidwood et al. 
 
 
 
 
 
http://eprints.gla.ac.uk/89949/ 
 
 
 
 
Deposited on: 23 January 2014 
 
 
© 2013 Braidwood et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0)  
License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further 
permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on 
how to request permission may be found at: http://www.dovepress.com/permissions.php
Oncolytic Virotherapy 2013:2 57–74
Oncolytic Virotherapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
57
R e V i e w
open access to scientific and medical research
Open Access Full Text Article
http://dx.doi.org/10.2147/OV.S52601
Oncolytic herpes viruses, chemotherapeutics,  
and other cancer drugs
Lynne Braidwood1
Sheila V Graham2
Alex Graham1
Joe Conner1
1Virttu Biologics Ltd, Department 
of Neurology, Southern General 
Hospital, Glasgow, UK; 2MRC-
University of Glasgow Centre for 
Virus Research, institute of infection, 
immunity and inflammation, College 
of Medical, Veterinary and Life 
Sciences, Jarrett Building, University 
of Glasgow, Glasgow, UK
Correspondence: Lynne Braidwood 
Virttu Biologics Ltd, Department of  
Neurology, Southern General Hospital,  
1345 Govan Road, Glasgow G51 4TF, UK 
Tel +44 141 445 1716 
Fax +44 141 445 1715 
email lynne.braidwood@virttu.com
Abstract: Oncolytic viruses are emerging as a potential new way of treating cancers. 
They are selectively replication-competent viruses that propagate only in actively dividing 
tumor cells but not in normal cells and, as a result, destroy the tumor cells by consequence 
of lytic infection. At least six different oncolytic herpes simplex viruses (oHSVs) have 
undergone clinical trials worldwide to date, and they have demonstrated an excellent 
safety profile and intimations of efficacy. The first pivotal Phase III trial with an oHSV, 
talimogene laherparepvec (T-Vec [OncoVexGM-CSF]), is almost complete, with extremely 
positive early results reported. Intuitively, therapeutically beneficial interactions between 
oHSV and chemotherapeutic and targeted therapeutic drugs would be limited as the virus 
requires actively dividing cells for maximum replication efficiency and most anticancer 
agents are cytotoxic or cytostatic. However, combinations of such agents display a range of 
responses, with antagonistic, additive, or, perhaps most surprisingly, synergistic enhance-
ment of antitumor activity. When synergistic interactions in cancer cell killing are observed, 
chemotherapy dose reductions that achieve the same overall efficacy may be possible, 
resulting in a valuable reduction of adverse side effects. Therefore, the combination of an 
oHSV with “standard-of-care” drugs makes a logical and reasonable approach to improved 
therapy, and the addition of a targeted oncolytic therapy with “standard-of-care” drugs 
merits further investigation, both preclinically and in the clinic. Numerous publications 
report such studies of oncolytic HSV in combination with other drugs, and we review their 
findings here. Viral interactions with cellular hosts are complex and frequently involve 
intracellular signaling networks, thus creating diverse opportunities for synergistic or addi-
tive combinations with many anticancer drugs. We discuss potential mechanisms that may 
lead to synergistic interactions.
Keywords: combination studies, herpes simplex virus, oncolytic virus, virotherapy
Introduction
Using viruses to treat cancer is not a new idea. For more than 100 years there have 
been clinical observations that cancer patients who contracted viral infections would 
enter periods of remission.1 During the 1950s and 1960s, there was considerable 
activity using wild-type viruses as anticancer treatments, but many of these trials 
were limited by the toxicity of the wild-type virus (for a historical perspective 
see Kelly and Russell1). Progress has only recently been possible as advances in 
virology and molecular biology have allowed either the identification of naturally 
occurring viruses with intrinsic tumor selectivity or by genetically engineering 
oncolytic viruses.
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Oncolytic herpes simplex virus (oHSV)
Oncolytic herpes viruses are attenuated, replication competent, 
herpes simplex type 1 viruses that selectively infect, replicate 
within, and lyse cancer cells. One of the first reports of an 
oncolytic virus being used for cancer therapy was in the early 
1990s when Martuza et al2 showed that a replication competent 
thymidine kinase negative herpes simplex virus (HSV)-1 mutant 
effectively prolonged survival of nude mice bearing intracranial 
glioma. Since then, numerous oHSVs have been described, most 
of which have deletions in either RL1, UL39, or both.
ICP34.5, the protein product of the γ34.5 gene, is a spe-
cific determinant of neurovirulence. It plays a key role by 
facilitating escape from a major host defense mechanism 
involving the protein kinase R-mediated innate immune 
response pathway by directly interacting with protein phos-
phatase 1α to dephosphorylate eIF2α (Figure 1).
In contrast, oncolytic HSV, which lacks functional 
ICP34.5 protein, cannot dephosphorylate eIF2α. Thus, infec-
tion with an ICP34.5 null virus causes the host cell to shut 
down protein synthesis, hence, preventing the virus from 
replicating in normal cells. Cancer cells, however, in the 
course of transforming to malignant cells have impaired anti-
viral mechanisms that permit unimpeded viral replication.3
UL39 is the HSV gene encoding for the large subunit of 
ribonucleotide reductase (RR), the main rate limiting enzyme for 
viral DNA synthesis and replication, controlling the nucleotide 
substrate pool by regulating the conversion of ribonucleotides 
to deoxyribonucleotides. HSV RR is required for growth in 
nondividing cells but not in rapidly dividing cells, in which there 
is ample cellular RR for the virus to utilize. Oncolytic HSV with 
a defective UL39 gene exclusively replicates in and lyses rapidly 
dividing cancer cells, as such cells provide sufficient levels of 
RR activity4 (for comprehensive review of oHSV see Cassady 
and Parker,5 Manservigi et al,6 and Varghese and Rabkin7).
Modified (armed and targeted) oHSV
The concept of using viral vectors to deliver therapeutic genes 
to tumors is well established. Many studies have evaluated 
both the oncolytic and antitumor activity, and the antitumor 
immune response of oncolytic viruses engineered to express 
either immunostimulatory genes or therapeutic genes, includ-
ing those that can activate prodrugs.
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Figure 1 HSV-1 can overcome normal cells protective block in protein synthesis: 1. HSV-1 enters the host cell and begins replication. 2. Complementary RNA anneal to 
produce dsRNA. 3. PKR binds dsRNA, dimerizes resulting in activation and autophosphorylation. 4. Phosphorylated PKR selectively phosphorylates elF2α. 5. Phosphorylated 
elF2α causes the host cell to shutdown translation thereby preventing viral replication. 6. HSV produced iCP34.5 which forms a protein complex with PP1α. 7. The iCP34.5 
PP1α complex dephosphorylates elF2α so the viral replication (8) can continue unchecked.
Abbreviations: HSV, herpes simplex virus; PKR, protein kinase R; eiF2α, eukaryotic initiation factor 2; PP1α, protein phosphatase 1 alpha; iCP, infected cell polypepetide; 
P, phosphorylation.
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The therapeutic efficacy of oncolytic HSV vectors encom-
passes two modes of action: direct oncolysis by the virus 
itself and indirect induction of an antitumor response. By 
arming viruses with genes that encode for immunomodula-
tory proteins such as IL(interleukin)-12,8-10 IL-2,11 soluble 
B7.1-Ig,12 or granulocyte macrophage colony-stimulating 
factor (GM-CSF)13–16 to help promote the antitumor immune 
response, the modified viruses are more efficacious.
Virus-directed enzyme prodrug therapy systems have also 
been utilized with oncolytic HSV. There are numerous reports 
of viruses that have been modified to code for enzymes that 
catalyze prodrugs into active substrates, such as HSV1yCD, a 
modified HSV coding for the yeast cytosine deaminase (CD) 
enzyme. HSV1yCD converts the nontoxic 5-fluorocytosine 
into fluorouracil (5-FU), a highly toxic chemotherapeutic 
agent,17 rRp450 carrying rat cytochrome P450 (CYP2B1) 
(which converts cyclophosphamide into the alkylating toxin 
phosphoramide mustard),18 and nitroreductase, which con-
verts the prodrug CB1954 to an active alkylating agent.19 
The extensive field of oncolytic HSV vectors modified for 
enhanced efficacy is beyond the scope of this review; the 
major approaches are detailed here but reviewed in greater 
detail by Varghese and Rabkin.7
Table 1 lists the principal oHSV in clinical development. 
At least six different oHSV have undergone clinical trials 
worldwide to date. oHSV have demonstrated excellent safety 
profiles and, in numerous studies, signals of efficacy. The 
first Phase III trial with an oHSV, talimogene laherparepvec 
(T-Vec [OncoVexGM-CSF]) has almost been completed. Ini-
tial extremely encouraging findings of the trial have been 
reported, with T-Vec demonstrating a statistically significant 
improvement in durable response rate.20
Oncolytic viruses in combination  
with chemotherapy
The use of many chemotherapeutic agents is limited by 
severe dose limiting toxicities and the emergence of resistant 
disease.21 In comparison, the mode of action of oncolytic 
viruses (lytic infection) means that cancer cells are unlikely 
to become resistant to them. Furthermore, oncolytic viruses 
have a high therapeutic index (ie, the comparison of the 
amount of a therapeutic agent that causes the therapeutic 
Table 1 Oncolytic HSVs in clinical trials
HSV strain Genetic modification Stage/clinical indication Results References
OncoVex  
GM-CSF (T-Vec)
Deletion in both copies of  
iCP34.5 + iCP47 disruption
Phase i/ii and iii melanoma 
Head and neck cancer 
Advanced metastatic melanoma
evidence of virus replication  
in injected and adjacent uninjected  
tumors (head and neck). Regression  
of injected and uninjected tumors in  
late stage melanoma. 
Ongoing
13,20,97,98 
71
R7020 (NV1020) Deletion of one copy of  
iCP34.5 + tk under iCP4  
promoter control + deletion  
in UL24, 55, and 56
Phase i and ii colorectal cancer  
liver metastases
in Phase ii disease stabilization in  
40%–45% of cases.
99–102
G207 Deletion in both copies of  
iCP34.5 + disruption of UL39
Phase i, iB, and ii recurrent brain  
cancer (glioma, astrocytoma, and  
glioblastomas)
well tolerated. evidence of viral  
replication and radiographic and  
neuropathological signs of  
antitumor activity.
103–109
HSV1716 Deletion in both copies of  
iCP34.5
Glioma Phase i 
Melanoma 
HNSCC 
Non-CNS solid tumors 
Malignant pleural mesothelioma
well tolerated, no toxicity. in  
Phase i/ii (recurrent glioblastomas)  
three out of 12 patients showed  
disease stabilization. No toxicity  
in melanoma or HNSCC. evidence  
of viral replication in tumors. 
Ongoing Phase i 
Ongoing Phase i/iia
110–114,129,130
HF10 Spontaneous generation  
of HSV-1 variant
Pancreatic cancer 
Recurrent breast cancer 
Bladder cancer 
HNSCC
115–122
rRp-450 iCP6 deleted and expresses  
prodrug enzyme for  
cyclophosphamide (ratCYP2B1)
Phase i liver metastases and  
primary liver tumors
Ongoing 131
Abbreviations: HSV, herpes simplex virus; iCP, infected cell polypepetide; tk, thymidine kinase; UL, unique long; HNSCC, head and neck squamous cell carcinoma; CNS, 
central nervous system.
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effect, to the amount that causes toxicity) with very limited 
toxicities. Table 2 summarizes the potential advantages of 
oncolytic virotherapy.
Viral infection initiates many complex host defense path-
ways;22 however, viruses have coevolved equally complex coun-
termeasures to circumvent these activities.23,24 Many of these 
countermeasures are retained by their oncolytic variants (Table 3 
outlines the main cellular and viral pathways activated upon viral 
infection). As chemotherapeutic and targeted anticancer agents 
target key cellular processes that also involve complex intracel-
lular signaling networks, there are extensive opportunities for 
antagonistic and synergistic interactions with oncolytic viruses, 
and these need to be explored and understood as the clinical 
acceptance of oncolytic HSV looks increasingly likely.25
Combining these two very different modalities in order to 
increase cancer cell killing is a rational approach. The clinical 
implications of this combination therapy are not limited to 
enhanced efficacy. The dose reduction index, the most relevant 
clinical parameter derived by Chou and Talalay analysis,26 reveals 
the potential for significant dose reductions without compromis-
ing tumor cell kill. Reducing the dose of drugs such as chemo-
therapeutics would minimize the toxicity and may allow patients 
to remain on an otherwise intolerable regime, or increase their 
quality of life whilst still receiving treatment for their disease.
Since the initial groundbreaking studies by Toyoizumi et al27 
with HSV1716 and four standard chemotherapeutic drugs, 
methotrexate, cisplatin, mitomycin C, and doxorubicin, there 
have been many reports of the increased efficacy of oHSV 
in combination with a wide range of existing and potentially 
new anticancer drugs. Tables 4–8 present the wide variety 
of different combinations that have been examined, and 
also summarize the results. The aim of this review is not to 
discuss the individual results presented in these tables, but 
to attempt a mechanistic overview that relates to their find-
ings. Crucially, there are a number of reasons why oncolytic 
virus therapy in combination with chemotherapeutic agents, 
or other anticancer treatments, will be beneficial. Firstly, the 
mode of action of oncolytic viruses is completely different 
from chemotherapeutics and they are not, therefore, in direct 
competition. Secondly, oncolytic cell killing is independent 
of the many genomic alterations that lead to drug-resistant 
tumors and so may be effective even in drug-resistant cells.
The most widely used method of studying drug/drug (or 
virus/drug) interactions between two modalities in vitro is 
using the methods of Chou and Talalay.26,28 This type of analysis 
is one of the few available that identifies beneficial interactions 
based on an extrapolated equation. The possibility of predicting 
a false positive is minimized as the analysis takes into account 
both the potency (the IC
50
 [half the maximal inhibitory con-
centration] or the LD
50
 [median lethal dose]) and the slope of 
the dose effect curves (m-value) in the precise analysis of two 
therapeutic combinations. The method defines the expected 
additive effect of two (or more) agents and quantifies synergy 
or antagonism by way of how different the measured effect is 
from the expected additive effect. The equations are detailed 
elsewhere.26,28,29 Interpretation of the combination index (CI) 
values are defined as: CI =1 indicates an additive effect; a CI 
of ,1 indicates synergy; and a CI .1 indicates antagonism. 
Synergy is the working together of two agents to produce a 
result greater than the sum of their individual effects, while 
antagonism is less than that of an additive effect.
Table 3 Main cellular and viral pathways activated upon viral 
infection
Name of  
HSV-1 protein
Pathway
Vhs inhibits iRF3 and NF-kB 
inhibits iFN-induced STAT1 nuclear accumulation 
and phosphorylation 
inhibits eiF2α phosphorylation
iCP34.5 Downregulates MHC class ii cell surface expression 
inhibits eiF2α phosphorylation
iCP0 inhibits iRF3/iRF7 to repress iSG production 
Disrupts ND10 domains 
Degrades TLR adaptor proteins MyD88 and Mal
iCP27 inhibits iRF3 and NF-kB 
inhibits iFN-induced STAT1 nuclear accumulation 
inhibits eiF2α phosphorylation
US11 Prevents eiF2α activation via an interaction with PKR
US3 Controls TLR3 RNA levels
Abbreviations: HSV-1, herpes simplex virus 1; iCP, infected cell polypepetide; iRF3, 
interferon regulatory factor 3; iRF7, interferon regulatory factor 7; NF-κB, nuclear 
factort kappa light chain enhancer of activated B cells; iFN, interferon; STAT1, signal 
transducer and activators of transcription 1; eiF2α, eukaryotic initiation factor 2; 
Vhs, virion host shutoff protein; MHC, major histocompatibility complex; ND10, 
nuclear domain 10; TLR, toll like receptor; MyD88, myeloid differentiation primary 
gene (88); Mal, myelin and lymphocyte protein; iSG, interferon stimulated gene; 
RNA, ribonucleic acid.
Table 2 Advantages of oncolytic virotherapy
Feature Advantage
Replicates within tumor cells to  
increase viral dose
Amplification leads to oncolysis in 
cells beyond those initially infected 
increases therapeutic index
Replicates only within tumor cells Minimal toxicity to normal tissues
Can be used safely with other  
cancer treatments and may have  
synergistic effect
Increased efficacy of combined 
treatment
Can also be engineered or armed  
to carry a wide variety of transgenes  
to enhance the therapeutic effect  
such as prodrugs or inducers of  
immunological response
Dual effect of viral oncolysis and 
the added effect of the prodrug or 
immune stimulator
Some evidence that oHSV are  
capable of targeting and  
eliminating cancer stem cells
eliminates the population of 
cells that are often resistant to 
chemotherapy and radiotherapy
Abbreviation: oHSV, oncolytic herpes simplex virus.
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Table 4 Oncolytic viruses and chemotherapeutic agent
oHSV Drug Cell line Cancer type In vitro In vivo Reference
HSV1716 Cisplatin UM_SCC 
14CUM-SCC 22A 
UM-SCC 22B
HNSCC 
HNSCC 
HNSCC
Additive 
Additive 
Additive
ND 
ND 
ND
114
HSV1716 Cisplatin, 
doxorubicin, 
mitomycin C,  
methotrexate
NCi-H460 NSCLC Additive ND 27
NV1066 Cisplatin H-2452, H-Meso, 
H-2373, H-28 
JMN, Meso-9 
MSTO-211H 
VAMT, 
H-2052 
Meso-10
MPM Synergistic 
Synergistic 
Synergistic 
Synergistic 
Additive 
Additive 
Additive
ND 
ND 
ND 
ND 
ND 
ND 
ND
41
G207 Cisplatin SCC-25/CP 
Sq20B 
UMscc-38
HNSCC No effect 
ND 
ND
ND 
No effect 
Additive to synergistic
123
G47Δ Cisplatin LNCaP Prostate cancer Antagonistic ND 89
OncoVex- 
GALV/CD
Cisplatin eJ 
T24 
TCCSUP-G 
Bladder transitional  
carcinoma
Antagonistic 
Antagonistic 
Antagonistic
ND 
ND 
ND
65
rRp450  
(CYP2B1)
Cyclophosphamide Rh30 Alveolar  
rhabdomyosarcoma
ND enhanced 54
G47Δ Doxorubicin LNCaP Prostate cancer Antagonistic ND 89
G207 Doxorubicin KAT4 
DRO90-1
Anaplastic thyroid  
cancer
Additive 
Additive
enhanced 
ND
87
G47Δ Docetaxol LNCaP 
DU145
Prostate cancer Synergistic 
Synergistic
enhanced 
ND
89
G207 erlotinib STS26T MPNST Additive Not enhanced 94
G47Δ etoposide LNCaP Prostate cancer Antagonistic ND 89
G207 Fluorodeoxyuridine HCT8 Colon cancer Synergistic ND 42
G207 5-fluorouracil KiGB-5 (murine) 
MKN45 (human)
Gallbladder 
Gastric cancer
enhanced 
enhanced (viral  
replication)
enhanced  
(Syrian hamster) 
enhanced (SCiD mouse)
44
NV1020 5-fluorouracil HT29 
wiDr 
HCT116 
CT-26
Colon cancer 
Colon 
Colon 
Colon
enhanced 
enhanced 
enhanced 
ND
ND 
ND 
ND 
enhanced
45
NV1066 5-fluorouracil Hs 700T 
PANC-1 and PaCa-2
Pancreatic cancer 
Pancreatic cancer
Synergistic 
Synergistic
ND 
ND
39
OncoVex- 
GALV/CD
5-fluorouracil A549, H460 
CAPAN-1, MiA PACA-2,  
BXPC-3 
HCT-116, HT-29, Sw620 
9L LacZ (rat)
Lung cancer 
Pancreatic cancer 
 
Colon cancer 
Gliosarcoma
enhanced 
enhanced 
 
enhanced 
ND
ND 
ND 
 
ND 
enhanced
124
NV1066 Gemcitabine Hs 700T 
PANC-1 and PaCa-2
Pancreatic cancer 
Pancreatic cancer
Synergistic 
Synergistic
ND 
ND
39
R3616 
hrR3
Gemcitabine CAPAN1 and PaCa-2 
Sw1990
Pancreatic cancer 
Pancreatic cancer
ND 
ND
enhanced both cell lines 
Not enhanced
64
OncoVex- 
GALV/CD
Gemcitabine eJ 
T24 
TCCSUP-G 
KU19-9
Bladder transitional  
carcinoma
Antagonistic 
Synergistic  
Antagonistic 
Antagonistic
ND
ND
ND 
ND
65
HF10 Gemcitabine CT26 Murine colorectal  
model
Antagonistic if given 
together Synergistic if 
GeM is pretreatment
enhanced effect in both  
injected tumor and  
distal tumor
88
(Continued)
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Table 4 (Continued)
oHSV Drug Cell line Cancer type In vitro In vivo Reference
NV1020 irinotecan (SN38) HT29 and wiDr 
HCT-116
Colon cancer enhanced 
enhanced
ND 
ND
45
MGH2 irinotecan (SN38) Gli36ΔeGFR  
U87ΔeGFR 
U251 
T98G
Glioma enhanced 
enhanced 
enhanced 
enhanced
enhanced 
ND 
ND 
ND
59
G207 Mitomycin C OCUM-2MD3 
MKN-45-P
Gastric cancer Synergistic 
Synergistic
enhanced 
ND
36
NV1066 Mitomycin C KU19-19 
SKUB
Bladder transitional  
carcinoma
Synergistic 
Synergistic
ND 
ND
126
OncoVex-
GALV/CD
Mitomycin C eJ 
T24 
TCCSUP-G 
KU19-9
Bladder transitional  
carcinoma
Synergistic 
Synergistic 
ND
Synergistic
ND 
ND 
ND 
ND
65
NV1020 Oxaliplatin HT29 and wiDr 
HCT-116
Colon cancer 
Colon cancer
enhanced 
enhanced
ND 
ND
45
G207 Paclitaxel KAT4 
DRO90-1
Anaplastic thyroid  
cancer
Synergistic 
Synergistic
enhanced 
ND
87
NV1023 Paclitaxel KAT4 
DRO90-1
Anaplastic thyroid  
cancer
Synergistic 
Additive
ND 
ND
87
G47Δ Paclitaxel LNCaP 
DU145
Prostate cancer Synergistic 
Synergistic
ND 
ND
89
MGH2 Paclitaxel MDA-MB-435S Mammary carcinoma ND enhanced 127
G207 Temozolomide U87 
U87-dnp53 
U373 
T98 
U87MGMT
Malignant glioma Synergistic 
Synergistic 
Synergistic 
Synergistic (with  
O6-benzylguanine) 
Synergistic (with  
O6-benzylguanine)
enhanced 
ND 
ND 
ND 
ND
128
G47Δ Temozolomide GBM13 
BT74 
U87MG 
T98 
GBM4 
GBM6 
GBM8
Glioma stem cells 
(TMZ resistant/ 
MGMT+ve) 
 
Glioma 
Glioma 
Glioma stem cells 
(TMZ sensitive/ 
MGMT-ve)
No synergy 
No synergy 
No synergy 
No synergy 
Synergistic 
Synergistic 
 
Synergistic 
ND  
Not enhanced (enhanced  
in the presence  
of + O6-benzylguanine) 
ND 
ND 
ND
ND 
 
enhanced
37
G207 Vincristine KFR 
KF-RMS-1
Rhabdomyosarcoma enhanced 
enhanced
enhanced 
enhanced
90
NV1042 Vinblastine CwR22 
PC3
Prostate Synergistic 
Synergistic
enhanced 
ND
78
Abbreviations: MPM, malignant pleural mesothelioma; oHSV, oncolytic herpes simplex virus; TMZ, temozolomide; HNSCC, head and neck squamous cell carcinoma; ND, 
not done; MPNST, malignant peripheral nerve sheath tumor; GeM, gemcitabine; MGMT, methylguanine DNA ethyltransferase.
Table 5 Oncolytic viruses and mTOR inhibitors
oHSV Drug Cell line Cancer type In vitro In vivo Reference
Baco-1 Rapamycin HepG2 
HuH-7 
MDA-MB-231 
eC9706 
MCF-7 
HeLa
HCC 
HCC 
Breast cancer 
esophageal 
Breast cancer 
Cervical
No effect 
No effect 
No effect 
Additive 
Additive 
Additive
ND 
ND 
ND 
Additive 
ND 
ND
46
MG18L BeZ235 GBM4 
GBM8 
GBM13 
BT74
Glioma stem cells No effect 
No effect 
Synergistic 
No effect
ND 
ND 
ND 
ND
85
Abbreviations: oHSV, oncolytic herpes simplex virus; HCC, hepatocellular carcinoma; ND, not done.
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Chou and Talalay26 analysis can also be used effectively 
in vivo, but it is more common practice, as reported in the 
literature, to look for differences in tumor growth between 
treatment groups and to use analysis of variance or t-tests 
to determine if the differences (often either tumor volume 
or length of survival) between groups are significant. 
 Information on synergy and/or enhanced efficacy of combi-
nations will also come from clinical studies. Most patients 
that take part in new cancer therapy trials have already had, 
or are currently being treated with, the standard treatment 
for their particular disease, and it will be interesting to see if 
any group treated with oHSV and another agent respond bet-
ter or worse than predicted. There are a number of different 
ways in which an oHSV in combination with an anticancer 
drug can be synergistic and these are discussed below.
Compounds that increase the 
replicative capacity of the virus
Oncolytic HSV have selective replication competence in 
cancer cells and, by increasing the replicative capacity of 
the virus within those cells, the number of progeny viruses 
produced during a cycle of infection could be increased 
(Figure 2).
Differentiating inducing agent hexamethylene bisacet-
amide (HMBA) has been shown to improve viral yield, with 
up to a 10,000-fold increase in vitro for an ICP34.5 null virus, 
R849, at low MOI (multiplicity of infection). HSV immediate 
early gene expression (Figure 4 shows the basic HSV replica-
tion cycle) was also increased with HMBA.30 Mice treated 
with both HMBA and R849 virus had significantly smaller 
tumor burden and survived longer than either virus or HMBA 
treatment alone, with increased levels of HSV transcripts of 
immediate early, early, and late genes in the combination 
treatment group. This suggests HMBA may increase and/
or activate cellular proteins such as transcription factors, 
which act to improve viral yield. HMBA is a drug that was 
thought to have some potential as a stand-alone anticancer 
agent; however, the level of drug required for such anticancer 
activity could not be achieved in patients.31 In the study with 
oHSV, a much lower dose of drug was able to be used; one 
which could easily be achieved in patients and potentially 
would act as a promoting agent for oncolytic therapy.
Table 6 Oncolytic viruses and Pi3K inhibitors
oHSV Drug Cell line Cancer type In vitro In vivo Reference
R7041 LY294002 U87 Glioma Synergistic enhanced 86
MG18L LY294002 GBM4 
GBM8 
GBM13 
BT74 
U87 
T98G
Glioma stem cells 
Glioma
Synergistic 
No effect 
Synergistic 
Synergistic 
Synergistic 
Synergistic
ND 
ND 
ND 
enhanced 
ND 
ND
85
MG18L GDC-0941 GBM4 
GBM8 
GBM13 
BT74 
U87 
T98G
Glioma stem cells 
Glioma 
Glioma
Synergistic 
No effect 
No effect 
Synergistic 
Synergistic 
Synergistic
ND 
ND 
ND 
ND 
ND 
ND
85
Abbreviations: oHSV, oncolytic herpes simplex virus; ND, not done; Pi3K, phosphatidylinositide 3-kinases.
Table 7 Oncolytic viruses and HDAC inhibitors
oHSV Drug Cell line Cancer type In vitro In vivo Reference
G47Δ Trichostatin A U87 
T98 
Sw480 
HeLa 
MCF-7
Glioma 
Colon cancer 
Cervical cancer 
Breast cancer
Synergistic 
Synergistic 
Synergistic 
Synergistic 
Additive
enhanced 
ND 
enhanced 
ND 
ND
65
R849 Trichostatin A SAS 
Ca9-22 
HSC
Oral SCC enhanced
ND
ND
ND
ND
ND
132
rQNestin34.5 Valproic acid U251 
U87Δ eGFR
Glioma ND 
ND
ND 
enhanced
133
Abbreviations: oHSV, oncolytic herpes simplex virus; SCC, squamous cell carcinoma; ND,  not done; HDAC, histone deacetylase.
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Another mechanism for increasing viral yields may be 
to temporarily block apoptosis. Upon viral infection, one 
of the cellular host responses is to induce apoptosis in 
infected cells and in cells surrounding infected cells (Fig-
ure 3) in order to limit the ability of the virus to replicate 
and spread. Therefore, by blocking apoptosis temporar-
ily, there is the potential for improving the propagation 
of viral progeny, maximizing the lateral spread of virus 
and increasing tumor destruction. Wood and Shillitoe32 
reported on increased viral replication in the presence of 
zVAD-fmk; a pan caspase inhibitor that has previously been 
shown to prevent HSV-1-induced apoptosis.33 The authors 
showed that the inhibitor increased levels of replication 
in an ICP34.5 null mutant back to the levels of wild type 
HSV-1. Stanziale et al34 also reported increased apoptosis 
in cells that neighbored NV1066-infected cells and could 
mitigate this effect with treatment with an inhibitor of apop-
tosis: N-acetylcysteine. This suggests that the increased 
viral yield seen with the caspase inhibitors is likely to be 
due to neighboring noninfected but alarmed cells being 
prevented from initiating apoptosis and, therefore, become 
lytically infected with virus.32,34 Eisenberg et al35 reported 
that hyperthermia potentiates oncolytic viral killing. 
After hyperthermic insult, the heat shock protein Hsp72 
is upregulated, which inhibits cellular apoptosis, thereby 
allowing increased viral replication and, in turn, enhanced 
tumor kill. This finding has great potential as, in a clinical 
setting, the application of heat is likely to be noninvasive 
and relatively toxicity free.
Compounds that increase cell  
permissiveness to oHSV
Many chemotherapeutic drugs are DNA damaging agents 
and, following exposure to such agents, cells upregulate their 
DNA damage repair pathways. Such upregulation appears to 
be beneficial for oncolytic viral replication; mitomycin C,36 
Table 8 Oncolytic viruses and others
oHSV Drug Cell line Cancer type In vitro In vivo Reference
OncdSyn Thalidomide 4T1 Breast ND enhanced 134
R849 Hexamethylene 
bisacetamide
Ca9-22 
SAS 
F1
Oral SCC enhanced 
enhanced 
enhanced
ND
ND
enhanced
30
Abbreviations: oHSV, oncolytic herpes simplex virus; SCC, squamous cell carcinoma; ND,  not done.
A
B
C
Cancer cell Virus replicates
Virus does not replicate
Healthy normal cell
Cancer cell Virus replicates
Figure 2 increasing replicative capacity of the virus: (A) in normal cells the virus does not replicate. (B) in a cancer cell the virus replicates, lyses the cell and produces viral 
progeny that go on to infect further cancer cells. (C) in the presence of certain drugs the virus can produce more viral progeny. Upon lysis more progeny virus are released – 
potentially increasing the number of cells that can be infected.
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temozolomide,37,38 and 5FU39 have all been shown to increase 
oncolytic HSV replication.
Growth arrest and DNA damage-inducible protein 
GADD34 is induced by stressful growth arrest conditions and 
treatment with DNA-damaging agents. The carboxyl terminal 
of GADD34 bears significant homology with the virulence 
factor ICP34.5, which is deleted in some oHSV, eg, HSV1716, 
NV1066, R3613, and T-Vec (Table 1). Previous studies40 have 
Cancer cell Virus replicates
Cancer cell Virus replicates
Progeny virus fail to replicate
Oncolysis – viral spread and
release of tumor antigens
Infected cell
produces
interferons
which induce an
antiviral state
in neighboring
cells
Drug inhibits
IFN response
Figure 3 Anti-viral host response mediated by iFN (interferon) induces apoptosis of surrounding cells. By using drug to block innate antiviral defence mechanism the infected 
cell will not signal other nearby cells to ‘warn’ them about the virus, hence viral replication will occur.
Envelope
proteins
Tegument
Capsid
Virus uncoats and
capsid
transported to
nucleus
Nuclear membrane
Immediate Early → Early → Late
DNA
HSV1716
Figure 4 Herpes simplex virus (HSV) replication cycle HSV-1 is a double stranded DNA virus which encodes for around 100 transcripts and contains three main structural 
components. The central capsid (or nucleocapsid) contains the viral DNA. This is surrounded by an envelope. The tegument is located between the envelope and the capsid. 
HSV enters the host cell at either the cell surface or via pH dependent endocytosis through a process involving envelope glycoproteins. The tegument proteins are released 
into the cell and the capsid is transported to the nucleus where viral DNA is released into the nucleus. There are three classes of viral genes that are transcribed and 
translated in a specific order: Immediate Early (IE) genes, which encode for proteins that promote expression of viral genes and also have a role in innate immune invasion, 
early (e) are responsible for the replication of viral DNA and lastly Late (L) genes which include capsid, tegument and envelope proteins.
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shown that the carboxyl terminus of GADD34 can substitute 
for ICP34.5 in preventing premature shutoff of protein synthe-
sis, and ICP34.5 null mutants can use the host cell GADD34 
protein for viral replication. Thus, the presence of GADD34 in 
tumor cells following treatment with a DNA damaging agent 
would increase the number of cells permissive to oHSV infec-
tion and increase the viral spread through the tumor. Indeed, 
when GADD34 small interfering RNAs (siRNAs) were added 
to block GADD34 expression after treatment with a DNA 
damaging agent (cisplatin), the previously observed synergy 
with the oHSV NV1066 and cisplatin was abolished.41
Another potential mechanism for synergy with some 
oHSV is upregulation of cellular RR by DNA-damaging che-
motherapeutic agents.42 High throughput screening has been 
reported to identify small-molecule compounds that augment 
the replication of HSV G47Δ,43 and, of the 2,460 compounds 
screened, six compounds were identified and subsequently 
validated for enhanced G47Δ replication. Two of these com-
pounds, dipyridamole and dilazep, interfered with nucleotide 
metabolism by potently and directly inhibiting the equilibra-
tive nucleoside transporter-1 and were dependent on HSV 
mutations in ICP6, the large subunit of RR. Equilibrative 
nucleoside transporter-1 antagonists are thought to augment 
oHSV replication in tumor cells by increasing cellular RR 
activity.43 As oHSV with UL39 deletions can only replicate 
in cells with active cellular RR, increasing cellular RR will 
improve viral replication.
Nakano et al44 reported an upregulation in RR in tumors 
mediated by 5FU that augmented the therapeutic effect of 
G207. 5FU was also found to be synergistic both in vitro and 
in vivo with oHSV NV1020 (an oHSV with intact ICP6),45 
suggesting the effects of 5FU are not limited to upregulation 
of RR. The authors speculated that the synergy was in part 
due to the cells being sensitized to 5FU as the virus caused 
the cells to arrest in S phase of the cell cycle. They further 
speculated that the reduction in viral progeny could be due 
to the immune IFN (interferon)-γ response as well as the 
5FU-induced upregulation of cell death via molecules such 
as TRAIL (TNF [tumor necrosis factor] related apoptosis-
inducing ligand) and Fas ligand.
Rapamycin markedly increased the yield and dissemination 
of oHSV in semipermissive tumor cells both in vitro and in 
vivo but had no additional effect in cell lines that are permis-
sive to the ICP34.5 null mutant oHSV Baco1.46 The reason 
behind the observation is still unclear; however, inhibitors of 
the mTOR (mammalian target of rapamycin) signaling pathway 
increase permissiveness of resistant tumor cells to oncolytic 
myxoma virus,47 vesicular stomatitis virus,48 adenovirus,49 
and cytomegalovirus,50 suggesting that the mTOR signaling 
pathway has an important role to play in virotherapy.
Compounds that modulate  
the immune system
The immune response to oncolytic viral therapy is an essen-
tial factor determining the success of oHSV as an antitumor 
agent; it can be a hindrance if it causes premature viral 
clearance, or could be seen as a positive, with the virally 
infected tumor becoming a target for clearance by the 
immune system.
The immune response to viral infection is beyond the 
scope of this review, but for an excellent insight into this 
field see Paludan et al.22 Briefly, the immune reaction to a 
viral infection (oncolytic or otherwise) is a multipronged 
response. Very quickly upon infection, the innate immune 
response recruits natural killer (NK) cells, macrophages, and 
neutrophils to the site of infection and mediates a nonspecific 
viral clearance. NK cells appear to be an important player 
in the response to viral infection; patients with naturally 
occurring NK cell deficiencies (despite there being numerous 
different mutations that cause such deficiencies) have severe 
and recurrent herpes virus infections.51 NK cells, activated 
by macrophages secreting IL-12, mediate the lysis of virally 
infected cells by releasing cytotoxic granules containing lytic 
enzymes and by binding to apoptosis-inducing receptors on 
the infected cell. In addition, NK cells secrete IFN-γ, which 
activates further macrophages and, consequently, orchestrates 
the downstream adaptive immune response.
The oncolytic HSV rQNestin34.5 (ICP34.5 expression 
controlled by the nestin promoter) has been shown to induce 
a rapid recruitment of NK cells to orthotopic human glioblas-
toma xenografts with subsequent killing of the oHSV-infected 
xenograft cells by activated macrophages. Depletion of NK 
cells improved the oHSV efficacy in these glioblastoma 
models, further indicating the importance of the NK cells.52 
Previous studies have demonstrated that inhibition of the 
innate immune response using cyclophosphamide53–56 or mac-
rophage depletion57 enhances oHSV replication and efficacy. 
An oHSV variant, rRp450, with deleted ICP6 and incorpo-
rated cytochromeP450 transgene for direct cyclophosph-
amide activation has been described, and the virus enhances 
the antitumor effects of cyclophosphamide.18,54,58,59
Another key event in the immune response to viral infec-
tion is the secretion of IFN-γ (for an extensive review see 
Roizman40 and Bazan-Peregrino et al60). The cytokine IFN-γ, 
or type II interferon, is critical for innate and adaptive immune 
response to viral infection, partly from its ability to inhibit 
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viral replication directly, but, more importantly, also from its 
immunostimulatory and immunomodulatory effects. IFN-γ 
is produced predominantly by NK cells as part of the innate 
immune response, and by cluster of differentiation (CD)4+ T 
helper (Th)1 and CD8 cytotoxic T lymphocyte (CTL) effector 
cells once antigen-specific immunity develops.
Histone deacetylase inhibitors (HDIs) are a class of com-
pounds that appear to benefit HSV oncolysis, possibly via 
suppression of innate immune responses. Histone deacety-
lases (HDACs) have pleiotropic effects on cells through 
deacetylation of proteins, including histones, which then alter 
the epigenome and transcription profiles. Numerous HDACs 
have been targeted for drug discovery for cancer therapies, 
either for use as a single agent or in combination with che-
motherapeutic agents. Pretreatment with the HDI valproic 
acid was shown to enhance the oncolytic virus MGH2 and 
rQNestin34.5 replication and spread in tumors, and extended 
the survival of mice bearing intracerebral tumors.52,61 The 
authors attributed the synergy between HDIs and oHSV to 
inhibition of type I interferon responses that would usually 
restrict viral gene expression and replication.
Drugs that cause downregulation of the innate immune 
response can be synergistic with oncolytic viruses but there 
is also evidence of the immune response enhancing tumor 
clearance.62 Benencia et al63 reported that oHSV therapy 
was less effective in murine metastatic melanoma models 
lacking NK and T cell subsets. Similarly, HSV1716-induced 
expression of IFN-γ inducible chemokines was accompanied 
by a significant increase in the number of NK and CD8+ 
cells in the tumor microenvironment in a syngeneic ovarian 
carcinoma model.59,63
Synergy has also been reported with oHSV and com-
pounds that increase IFN-γ production.64 The authors found 
that pretreating tumor cells with gemcitabine before oHSV 
significantly reduced tumor growth in vivo. Pretreatment 
was necessary as the drug itself induces early termination 
of DNA synthesis, which prevents replication of oncolytic 
viruses.39,64–66 Gemcitabine selectively kills myeloid-derived 
suppressor cells, which inhibit IFN-γ production by CD8+ 
cells. So, when myeloid-derived suppressor cells themselves 
are killed, CD8+ T cells will secrete higher levels of IFN-γ, 
thus directing more T cells to tumor sites, which results in an 
improved antitumor response. In addition, IFN-γ can change 
the tumor microenvironment in terms of macrophages pheno-
type. Macrophages are classified as m1 (classically activated) 
or m2 (alternatively activated). During tumor progression 
there is a switch from m1- to m2-like phenotype that is 
believed to allow the tumor cells to avoid the immune system. 
Higher levels of IFN-γ can change the macrophage phenotype 
back to m1, resulting in the cancer cells being more likely to 
be tagged for destruction by the immune system.64
Recently, a number of immunotherapeutic agents have 
been approved as cancer treatments. Ipilimumab, a monoclo-
nal antibody that blocks the CTL-associated antigen 4 recep-
tor, which would normally inhibit cytotoxic T lymphocyte, 
for example, is approved for use in advance metastatic 
melanoma.67,68 It is by blocking the CTL-associated antigen 
4 receptor that CTLs are activated and can recognize and 
destroy cancer cells. As the presence of an oncolytic virus 
within a tumor will make the tumor more antigenic, there is 
good reason to think that the combination of oncolytic virus 
and immunotherapy will be synergistic and, indeed, there 
are many reports of improved efficacy of oHSV engineered 
to express genes that make immunomodulatory proteins 
including IL-12, IL-24, IL-4, RANTES (Regulated on Acti-
vation, Normal T cell Expressed and Secreted), CD80, and 
IFNα.68  Granulocyte-macrophage colony-stimulating factor, 
which generates an antitumor response by the recruitment 
and differentiation of activating dendritic cells in the tumor 
microenvironment, has been inserted successfully into 
T-Vec,69,70 and a clinical study investigating T-Vec in combi-
nation with ipilimumab is underway,71 with primary results 
expected in summer 2016.
Immunomodulatory drugs highlight the complexities of 
potential interactions between oHSV and anticancer agents, 
with synergy reported with drugs that inhibit or upregulate 
the immune system. It is likely that drugs that inhibit the very 
early innate immune response will allow the virus longer to 
enter cells and undergo initial viral replication, increasing the 
spread of the virus. Drugs that act by boosting later immune 
responses, such as upregulating T cells, mean that the infected 
tumor cells and potentially uninfected neighboring tumor cells 
are more likely to be targeted for destruction by the immune 
system. It will be interesting to see if downregulating innate 
immunity by HDIs, for example, and upregulating T cells by 
gemcitabine, would result in further synergistic effects when 
combined with an oncolytic virus. To date, no triple combina-
tions have been reported in the literature, probably due to the 
increasing complexity of such experiments.
Compounds that alter the tumor  
microenvironment
Angiogenesis is the formation of new blood vessels and, as 
tumors need blood vessels to grow and spread, inhibitors of 
angiogenesis, which prevent the formation of new blood ves-
sels, could potentially prevent or slow the growth or spread 
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of tumors. Unlike chemotherapeutic agents, angiogenesis 
inhibitors will not kill cancer cells directly but instead prevent 
tumors from growing, so potentially, in order to completely 
eradicate a tumor, an antiangiogenic drug would have to be 
given in combination with a modality that kills cancer cells, 
such as an oncolytic virus.
Vascular endothelial growth factor (VEGF) is a key com-
ponent in tumor angiogenesis and is overexpressed in many 
human tumors. It has numerous effects on tumor vasculature 
such as increased vasodilation and permeabilization, and 
inhibitors of VEGF, such as Avastin®, sorafenib, and suni-
tinib, appear to “normalize” tumor vasculature, potentially 
enhancing localization of systemic oncolytic virus. ICP34.5 
null oHSV infectivity and cytotoxicity were diminished under 
hypoxic conditions (when the cells are deprived of oxygen) 
in several glioblastoma xenolines, which are cell lines main-
tained by xenograft passage.69 Normalization of the blood 
vessels by antiangiogenic agents may reduce hypoxia within 
the tumor microenvironment and potentially improve oHSV 
replication. However, other studies have shown improved 
oHSV replication in hypoxic conditions.70–73 Bevacizumab 
(Avastin®), a monoclonal antibody against VEGF A, had no 
effect on the spread or replication of oHSV in vitro. However, 
in vivo, in several studies using different xenograft models,74,75 
groups of mice receiving the dual therapy of both oHSV and 
Avastin® had tumors that were significantly smaller than 
tumors from either treatment alone. Results from these stud-
ies indicated that Avastin® improved replication and spread of 
the oHSV within the xenograft microenvironment. Although 
cytotoxic in vitro, in some xenograft models rRp450 had only 
mild antitumor effects.76 The host inflammatory response to 
rRp450 therapy was found to induce an acute neutrophil infil-
trate, a relative decrease of intratumoral macrophages, and a 
myeloid cell-dependent upregulation of host-derived VEGF. 
Bevacizumab and r84 (which selectively inhibit binding to 
VEGF receptor 2 but not VEGF receptor 1) enhanced the 
antitumor effects of rRp450 therapy, in part due to decreased 
angiogenesis. However, although neither bevacizumab nor 
r84 increased virus production or affected neutrophil infil-
tration, both partially mitigated virus-induced depletion of 
macrophages. Therefore, the enhancement in efficacy with 
the combination of oHSV therapy and anti-VEGF antibodies 
appears to be in part due to modulation of host inflammatory 
reaction to virus.
Vinblastine, a microtubule disrupting agent that has 
been shown to inhibit angiogenesis in humans77 and, in 
combination with the oHSV NV1042, showed increased anti-
tumor and antiangiogenic effects in vivo in prostate cancer 
models,78 provides further evidence that the combination of 
an antiangiogenic agent and an oncolytic virus may have 
clinical benefit. However, to the best of our knowledge, there 
are no preclinical published studies of oHSV in combina-
tion with small molecule VEGF receptor inhibitors such as 
sorafenib or sunitinib.
HSV DNA replication occurs in discrete compartments 
in the nucleus that assemble as prereplicative sites with 
viral DNA and the HSV DNA binding protein ICP8. HSV 
DNA polymerase and cellular factors are then recruited to 
these compartments for use in viral replication. The DNA 
damage and repair pathways repair the damage to the cancer 
cell DNA caused by treatment with DNA-damaging drugs 
such as temozolomide (TMZ). However, in the presence 
of oHSV infection, key components of these pathways are 
sequestered into discrete compartments for use in viral rep-
lication, hence are not available to repair the damage caused 
by drugs. Thus, the damage, in terms of number of cancer 
cells killed by a specific amount of drug, is greater in the 
presence of oHSV.37
Cellular kinases play a key role in the regulation of 
signaling events that govern multiple pathways affecting 
growth, proliferation, migration, and angiogenesis. These 
include PI3K (phosphatidylinositide 3-kinases)-Akt-mTOR 
and mitogen-activated protein kinases pathways, which are 
often mutated in cancer cells to support unchecked cellular 
replication. Inhibition of these pathways could potentially 
reduce tumor growth, and this is reflected in the inten-
sive drug development looking for PI3K-Akt-mTOR and 
mitogen-activated protein kinases inhibitors. For example, 
80% of glioblastomas are having genetic alterations in the 
PI3K-Akt-mTOR pathways and there are at least 10 different 
inhibitors in development.79 However, due to the high level 
of redundancy and cross regulatory feedback loops, mono-
therapy may be unlikely to have significant clinical efficacy;80 
for example, rapamycin only reduces mTOR activity for 
12 hours before another kinase substitutes and reengages the 
mTOR network.81 Furthermore, such inhibitors are likely to 
be cytostatic: they will stop the cancer cells from growing 
or dividing but will not eradicate them.
The PI3K-Akt-mTOR pathway is also important in viral 
replication (for a full review see Terada et al61 and Buchkovich 
et al82). Upon infection, viruses frequently activate this 
pathway to benefit from the survival signaling associated 
with Akt activation. One of the downstream effectors of 
activated Akt is the mTOR kinase, a component of the mTOR 
complexes (mTORC) 1 and 2. Activated mTORC1 is crucial 
for the maintenance of cap-dependent translation which is 
Oncolytic Virotherapy 2013:2 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
oHSV in combination with anti-cancer treatments
required by most mammalian DNA viruses and many RNA 
viruses. mTORC2 is less well understood, but is thought to 
have roles in Akt phosphorylation and the organization of 
the actin cytoskeleton. It would therefore seem reasonable 
to assume that inhibitors that block the function of mTOR or 
PI3K would not only block translation of cellular proteins but 
would drastically reduce the ability of viruses to replicate by 
virtue of stopping their cap-dependent translation. Theoreti-
cally, PI3K and mTOR inhibitors would be antagonistic if 
used in combination with oncolytic viruses. The literature, 
however, reveals diverse results that vary depending on the 
specific virus, the specific inhibitor, and the status of the 
cells used.
Breitbach et al83 found that compounds such as rapamy-
cin, which blocks the activation of mTOR, and PD098059, 
which blocks the activation of MAP (mitogen-activated 
protein) kinase, did not affect the ability of oHSV R3616 
to replicate in pancreatic tumor cells. Treatment with the 
inhibitor LY294002, which inhibits the PI3K pathway, pre-
vented the replication of R3616. Similarly, synergy was not 
observed between LY294002 and the ICP34.5 null oHSV, 
but was observed with oHSV mutants with a Us3 mutation.84 
The gene product of Us3 protects virus-infected cells from 
apoptosis; a cellular pathway that is often dysfunctional in 
tumors. Thus, Us3 mutants, whose replication would be 
inhibited by apoptosis in normal cells, would be selective 
for tumor cells, and the combination treatment of LY294002 
and Us3-null oHSV is synergistic due to enhanced apoptosis 
in the combination treated cells.85
Compounds that affect  
the cell cycle
Strong synergy between oHSV and trichostatin A (an HDAC 
inhibitor) was observed in a wide range of cancer and prolif-
erating endothelial cell lines but not in normal prostate or qui-
escent epithelial cells.86 Unlike other HDIs, the synergy was 
seen regardless of the dosing sequence of the oHSV (G47Δ) 
or trichostatin A. The synergy was attributed to reduced cyclin 
D1 expression in cells that normally have a high level of cyclin 
D (ie, cancer cells). The combination also inhibited secretion 
of the angiogenic factor VEGF, which correlated with the 
decreased vascularity within the tumor in vivo.
Another combination that appears to affect the cell cycle 
occurs between the oHSV G207 and paclitaxel. Paclitaxel 
is an approved cancer therapy that stabilizes microtubules 
and, as a result, interferes with the normal breakdown of 
microtubules during cell division. In the presence of pacli-
taxel, chromosomes are unable to achieve metaphase spindle 
configuration. This inability to form the correct formation 
blocks the progression of mitosis which in turn triggers 
apoptosis or the cell to revert to the G phase of the cell cycle 
without dividing. Despite the G207/paclitaxel combination 
being synergistic, oncolysis or viral replication was not 
increased.87 The authors concluded that they differentially 
affected cell cycle progression, either by the cells arresting 
in G1 (virus-mediated) or mitosis (paclitaxel-mediated), 
a combination that served to increase apoptosis further. 
Paclitaxel also showed synergy with other oHSV, HF10, 
and G47Δ, both in vitro and in vivo.88,89 The oHSV HF10 
has been studied alone and in combination with paclitaxel in 
colon cancer models.88 In vivo, the combination of HF10 and 
paclitaxel prolonged survival of mice bearing carcinomatous 
dissemination of CT26 tumors compared with the control 
groups. G47Δ also synergized with paclitaxel and the closely 
related docetaxel to enhance the in vitro killing of LNCap and 
DU145 prostate cancer cells.89 Docetaxel-induced accumula-
tion of the phosphospecific mitotic markers op18/stathmin 
or histone H3 was significantly reduced by G47Δ, and this 
correlated with enhanced apoptosis and required active virus 
replication. Another microtubule inhibitor, vincristine, was 
also shown to be synergistic with oHSV in rhabdomyosar-
coma xenografts.90
Cheema et al91 reported synergy with etoposide, an inhibi-
tor of topoisomerase II, and oHSV G47Δ in glioma stem cell 
xenografts. Gutermann et al45 found synergy with SN38 (the 
active metabolite of irinotecan, a topoisomerase I inhibitor) 
and NV1020 in a panel of human colon carcinoma cell lines 
in vitro. Synergy with irinotecan and MGH2 (an oHSV with 
UL39 and -γ34.5 deletions) was also reported in glioma, both 
in vitro and in vivo.59
Other compounds where synergy  
and/or enhancement is seen  
but the mechanism is unclear
Although not using an oHSV, Heo et al92 reported on the 
first clinical signs of positive interactions between onco-
lytic virotherapy and standard of care drugs with JX-594 
(an oncolytic pox virus) and sorafenib, a small molecule 
inhibitor of the signaling oncoprotein B-raf and VEGF 
receptor, which is licensed as a treatment for hepatocellular 
carcinoma. The authors reported that a number of patients 
treated with JX-594 and then sorafenib up to 8 weeks 
later had objective tumor responses (ie, tumor shrinkage) 
compared to zero in 15 untreated patients matched for age, 
stage, and sex. Furthermore, they also reported a complete 
cure in one patient treated with sunitinib, another inhibitor 
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similar to sorafenib, 8 weeks after JX-594 treatment. As the 
virus is likely to be cleared from the patient by 8 weeks, the 
mechanism by which the oncolytic virus can sensitize tumors 
to these inhibitors is unclear. Interestingly, the patients who 
have the best responses to sorafenib are those patients who 
have hepatitis C related hepatocellular carcinoma,93 suggest-
ing that there may be a therapeutic class effect where viruses 
sensitize tumors to VEGF receptor inhibitors.
Erlotinib, an epidermal growth factor receptor inhibitor, 
combined additively with two oHSV, G207, and hrR3 in 
order to enhance cytotoxicity in vitro in human malignant 
peripheral nerve sheath tumor cells often associated with Ras/
epidermal growth factor receptor hyperactivation; however, 
this effect did not translate into an in vivo malignant periph-
eral nerve sheath tumor xenograft model.94 Thalidomide, 
which is now approved for use in multiple myeloma patients, 
was found to have significant benefit in reducing tumor bur-
den in combination with OncdSyn (an NV1020-like oHSV) 
than either OncdSyn or thalidomide alone in a murine breast 
cancer model,95 though the mechanism is unclear.
Conclusion
Oncolytic viruses are a new and emerging treatment for 
cancer. As they become an established therapy, much 
attention will have to be paid to the interaction between 
current standard of care drugs and oncolytic viruses. So 
far, the signs are encouraging; not only can oHSV be 
given alongside other cancer treatments, but can actu-
ally result in an enhancement of efficacy in reducing 
tumor burden and improving survival. The majority of 
virus–drug combinations listed in Tables 4–8 show syn-
ergistic, enhanced, or additive effects, but this may in 
part reflect the fact that antagonistic combinations might 
not be submitted for  publication. Recently, Kulu et al96 
reported on the inhibition of HSV oncolysis in colon and 
pancreatic cancer cell lines in vitro when combined with 
5-FU, irinotecan, or  methotrexate. Their studies showed 
that replication of both ICP6 and/or ICP34.5 deleted 
oHSV was significantly reduced in HT29 and SW620 
(colon) and Capan-2 (pancreatic) cell lines. Others have 
reported additive/synergistic interactions (with respect to 
cell  killing) between 5-FU, irinotecan, and methotrexate 
(Table 2) with oHSV in diverse cell lines, including both 
colon and pancreatic lines. It is conceivable that the drugs 
can inhibit virus replication but the combined effects of 
virus and drug act in concert to enhance cell death, and 
seemingly conflicting results serve to illustrate our poor 
understanding of such interactions.
Furthermore, the sequence in which the drug and oHSV 
are given may impact on cell killing. For example, gemcit-
abine and HDIs such as valproic acid are synergistic when 
given as a pretreatment to the virus, thus sensitizing the tumor 
to virus, whereas sorafenib appeared to work better given 
after oncolytic virus; thus the virus is acting as the sensitizer. 
Similarly, when oHSV rRp450 was given before Avastin® 
(bevacizumab) there was a significantly prolonged survival 
compared to the same combination in reverse order.74
Many of the published combination studies examined 
the effects of combinations in vitro. These identify com-
binations that enhance cancer cell cytotoxicity. However, 
many of the interactions between oHSV and drugs either 
affect the tumor or host biology, and these interactions will 
only be seen in vivo. The immune system is a key player 
in the efficacy of any combination treatment; it appears 
that initial suppressing of the innate immune response in 
order to allow the virus to undergo replication, then an 
upregulation of the immune system to clear the virus and 
tumor, would be a rational strategy in terms of reducing 
tumor burdens.
The use of patient-derived tumor xenografts, where pri-
mary human tumors are transplanted into immune deficient 
mice within hours after the sample is collected, are increas-
ingly being used to predict the effectiveness of chemothera-
peutic drugs in patients. To our knowledge, such models have 
not been reported for testing combinations of oncolytic HSV 
together with chemotherapy or targeted drugs, but are likely 
to be valuable and should provide data that will improve 
decision making and accelerate development programs for 
virus/drug combinations.
As preclinical studies progress into the clinical setting, 
major progress in the understanding of oHSV in combination 
with other treatments is likely to occur. Early clinical trials 
usually involve patients who have already exhausted all the 
available standard treatment options, and even later Phase III 
trials will often compare standard of care versus standard of 
care plus oHSV. Such studies should help confirm preclinical 
findings on useful virus/drug combinations and hopefully 
bring benefit to cancer sufferers.
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